Walgreens teams up with Verily to tackle chronic conditions

Amy Baxter | | Health Exec | Precision Medicine

Walgreens Boots Alliance has teamed up with Verily, the life sciences unit of Google parent company Alphabet. The two companies will focus on improving outcomes for patients with chronic conditions, CNBC reported.

The partnership will deploy Verily’s technology at Walgreens’ pharmacies and specifically focus on medication adherence, an issue that costs the healthcare system about $100 billion to $289 billion annually.

The partnership may help Walgreens connect more technology to its growing healthcare services and could signal a move to fend off competitors like CVS Health, which recently acquired health insurance provider Aetna, and Amazon, which has continued to step into the pharmacy and healthcare space.

See the full story below:

Walgreens to tackle health-care costs with Alphabet’s Verily

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

AI in Healthcare
Nat’l Academy of Medicine sets ‘priorities for action’ as healthcare mulls next moves with AI

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

Cardiovascular Business
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.